35 posts not to miss from WCLC24 Day 4
The WCLC24 is took place at the San Diego Convention Center from September 7 to 10, 2024.
The International Association for the Study of Lung Cancer (IASLC) is a global, multidisciplinary organization committed to the eradication of all forms of lung cancer. The IASLC unites a diverse group of professionals – including medical, surgical, and radiation oncologists, as well as nurses, basic scientists, pathologists, radiologists, pulmonologists, statisticians, patient advocates, patients, and caregivers in – its mission to advance the science of lung cancer and enhance patient care.
Organized by the International Association for the Study of Lung Cancer (IASLC), this major conference is gathering leading experts, researchers, and oncologists to present and discuss the latest advancements in lung cancer research, treatment, and personalized therapies, fostering collaborative efforts towards overcoming the challenges of lung cancer.
Here are some Highlights from the WCLC24 Day 4:
“In this episode, Narjust Florez and Stephen V Liu recap WCLC24.
Jacob Sands discusses TROPION-Lung01 with datopotamab deruxtecan and DeLLphi-301 with tarlatamab. Hidehito Horinouchi reports results from the LUMINOSITY study, and Noemi Reguart gives some perspective on TRUST-II without talectrectinib. Listen Now.”
Faculty dinner at WCLC24 – a chance to reconnect with friends from around the world Narjust Florez, Justin Gainor, Tetsuya Mitsudomi, Jarushka Naidoo, Tina Cascone, Caicun Zhou, Junko Tanizaki, Wen-Zhao Zhong, Yilong Wu, Motoko Tachihara.
“Congrats to Leah Backhus for winning the WCLC24 Robert J. Ginsberg Lectureship Award for Surgery on her crucial work using precision oncology to improve lung cancer surveillance, using machine learning to move away from a one-size-fits-all model and incorporate ctDNA, radiomics, etc.”
“WCLC24 HEINE H. HANSEB LECTURESHIP AWARD for SMALL CELL LUNG CANCER to our friend and exceptional researcher Dr. Luis Paz-Ares. A well-deserved award for a pioneering researcher who has contributed to several cutting-edge advances in the field. SO PROUD!!!”
“WCLC24 I will always cherish this
The White Ribbon Project presented to me by Chris Draft.
with the signatures of Michigan NFL players in solidarity with the lung cancer community, patients, caregivers and researchers united on the fight against lung cancer.”
“Impactful work by Babalola Faseru, winner of the WCLC24 IASLC Lectureship Award for Tobacco Control and Smoking Cessation, on changing the cigarette cessation framework from an opt-in to an opt-out model. This approach increased quit rates at 1 month, though quit rates at 6 months were comparable. The costs are similar to other cessation interventions.”
“Great to be a part of the IASLC WCLC24 closing session on advancing patient advocacy worldwide. While spread across the world, we have 1 goal: improving outcomes for those with lung cancer. Thanks Dr Jhanelle Gray, Anabelle Gurwitch, Caleb Egwuenu, Shani Shilo and Lillian Leigh – fab session.”
Wrapping up WCLC24 with immense gratitude! A heartfelt thank you to Narjust Florez for opening so many doors and creating incredible opportunities. And a big shoutout to Laura Petrillo for her amazing partnership throughout the planning committee.
“Congratulations to WCLC24 chairs.
Sandip Patel, Narjust Florez, Linda Martin, Fabio Moraes for a memorable edition 50, and best of luck to our WCLC25 chairs.”
“Well WCLC2024 is a wrap!
Sandip Patel, Narjust Florez and their cochairs as well as the IASLC staff – outstanding job! All of the presenters and faculty were stellar! Thanks for making this WCLC one to remember! IASLC family.”
“Really exciting to watch Erica Warner present the initial results from the MGH FireHealthStudy.org at WCLC24.
Stay tuned to hear more soon! Also, we are looking for firefighters diagnosed with lung cancer to enroll – please refer such people to our website.”
“Just listened to this terrific WCLC24 Highlights Korean Podcast by Chul Kim. Tremendous value to having Lung Cancer Considered podcast in multiple non-English languages, allowing different flavors of medical culture and communication to be captured while important scientific advances are shared. Thanks to Stephen V Liu, Narjust Florez, IASLC for leading this effort!”
“To reach a global audience, IASLC has recorded WCLC24 podcast episodes in world languages. In this Lung Cancer Considered episode, Chunxia Su moderates a discussion in Mandarin about highlights from the conference with Dr. Huijuan Wang, Dr. Lin Wu.”
“Join us today to explore EGFR/HER2 exon 20, RET, MET, BRAF, and KRAS G12C, along with valuable patient perspectives. It will be an insightful session!”
“Join us today! The Rest of the Pie: State of the Art for “Other” Targets
Tuesday Sept 10 , 1:30 pm
room 32AB”
“Touching and emotional talk of Janet Freeman-Daily cancer patient, activist, research advocate. Cofounder Ros1Ders. Thank you for sharing your story to inspire others to live better lives.”
“Lung Radio-Oncologists: what we do matters. Getting this right increases survival. Time to be included in the development of combined modality trials from the beginning.
Too funny… x has just labelled this slide ‘adult content’. Wow WCLC2024 is more exciting than I thought!”
“Right now at the Advanced Cancer Survivorship session! Mariana Laloni from Grupo oncoclinicas is chairing.
Laura Petrillo will discuss Pall Care for Lung Cancer patients, and Paulo Bergerot will cover Exercise in Oncology. Don’t miss these insightful talks! Photo by Pedro De Marchi.”
“Why is my great colleague MarkLewis – oncologist extraordinaire simply the best of the best?
I deliver tissue-agnostic and age-agnostic Precision Medicine talks, but Mark takes it one step further with ‘Species-agnostic Passionate Medicine’ talks!
Every oncology meeting needs an emotional support puppy that can double up as a sniff dog to detect early cancers.”
“More photos from the halls of IASLC WCLC24.
Karen Reckampand I were catching up when we corralled Minghua Lu to join us in a photo op! Loved the catching up!!”
“Even if I don’t utter a word this is already shaping up to be the greatest presentation of my career.”
“Huge congrats to Jeff Yang for WCLC24 Clifton F. Mountain Lectureship Award for Staging for his and his team’s amazing work using AI to improve our ability to predict risk of recurrence in patients with stage 1 lung cancer and help the general public understand lung cancer staging.”
“Last day WCLC2024.
Cecilia Pompili presenting updates from the IASLC DEI task force Truly diverse panel co-chaired by Narjust Florez.
A brilliant initiative to understand the gaps, analyse and strengthen inclusivity.”
“Here at WCLC24 to speak on Sexual Health at the Advanced Cancer Survivorship session! It is so amazing that this important topic is included in this International lung cancer conference.”
“Dr. Susan Combs Scott of John Hopkins Thoracic Oncology with a detailed breakdown of all things exon 20 — HER2 and EGFR that is. Rapidly evolving space with many promising therapeutics that are hopefully nearing the clinic!”
“Dr. Geoffrey Liu presents data from TRUST-II, global phase II trial evaluating next-gen ROS1 TKI taletrectinib in patients with ROS1 NSCLC. PFS data – esp in 1L setting – awaited. Looking forward to additional data to be shared next week at ESMO. ”
“Truly amazing to see so many studies expand treatment options for pts with ROS1-rearranged lung cancer. Especially great that the global TRUST II trial showed findings consistent with TRUSTI, with responses to taletrectinib in pretreated and TKI-naive patients and promising brain responses.”
“Excited to share posters of our key research at WCLC24
- Pregnancy and Lung Cancer Registry. The world’s first registry tracking lung cancer during and after pregnancy!
- With Eyes on the Future. Evaluating immune-related adverse events in lung cancer patients on ICIs
“So proud of my amazing mentor Jessica J Lin for presenting updated efficacy, safety, and biomarker data for larotrectinib for patients with NTRK-rearranged brain cancer.
IRC-ORR 66%, median PFS 22 mo, median OS 39 mo.
Acquired resistance in 5 of 13 patients with post-progression biopsies.”
“WHAT A DAY FOR SPANISH RESEARCHERS!! FRED R. HIRSCH LECTURESHIP AWARD FOR TRANSLATIONAL RESEARCH goes to Montse Sanchez-Cespedes. Her tireles dedication in lung cancer translational research is advancing breakthroughs that are transforming patient care”
“Pleased to share an updated efficacy, safety, and biomarker analysis of Larotrectinib in TRK fusion+ NSCLC, presented at the WCLC24 today.
- NTRK gene fusions are rare (~0.2% in NSCLC) but present across a diverse spectrum of adult and pediatric cancers
- Larotrectinib is approved for tumor-agnostic use in patients with TRK fusion-positive cancers as a selective and CNS-active TRK inhibitor
- Today we provided updated efficacy and safety data from two clinical trials evaluating larotrectinib in patients with TRK fusion lung cancer after an additional 12 months of follow-up, as well as biomarker data
Among 32 patients included in this analysis, larotrectinib continued to demonstrate robust efficacy with an ORR 66% (and 67% among patients with known CNS metastases!)
- median DOR 34 months (f/u 26 mos)
- median PFS 22 months (f/u 28 mos)
- median OS 39 months (f/u 33 mos)
Responses seen regardless of the NTRK gene involved or the NTRK1-3 fusion partner
Durable responses (10 patients remaining on treatment at data cut-off)
- Baseline ctDNA detected NTRK fusions in 6 of 15 patients
- If ctDNA negative, may be non-diagnostic, should follow up with tissue NGS!
- On-target (NTRK) resistance alterations identified in 2 pts TP53 and KRAS mutations identified post-baseline
Larotrectinib is a very well-tolerated drug overall among patients in the clinic, and the updated analysis continues to support this
- TEAE and TRAE profile consistent with prior reports
- Predominantly grade 1/2 AEs
- One patient discontinued treatment due to TRAE (increased liver enzymes)
Must improve biomarker testing to identify patients who can benefit from effective therapeutic agents like Larotrectinib and to increase their reach to patients! Thankful to all investigators involved in these studies. Most importantly thankful to patients and caregivers whose generosity, strength and courage, and hope and faith in research enable advances.”
“Great presentation of our Florez Lab work about immune-related adverse events in lung cancer patients on ICIs
- SOB and cough were the most reported high-severity symptoms
- 50% on Pembrolizumab
- Nausea/abdominal pain and fatigue were also reported.”
“WCLC24 Meet-up. Happy to meet Fabio Moraes
IASLCC WCLC24 Co-chair.
Congratulations and huge thanks for the greatest-ever conference.”
“Wrapping up all the good things that I have lived through the IASLC 50th Anniversary. Best science, great friendships and strong collaboration across the globe to eradicate lung cancer everywhere and provide support to our patients and caregivers.”
“Mission accomplished! Speaking at WLCC24 San Diego today, about Targeted therapies for NSCLC – The Patient’s Perspective.’ Proud to join a global team.”
More posts about WCLC24 on oncodaily.com
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023